Greer Laboratories announces FDA Approval of Oralair for the treatment of grass pollen allergy

03-04-2014 Business Wire HealthComments (0)

BiotechnologyGREER LaboratoriesOralairPharmaceuticalUSA

Greer Laboratories, a leading developer and provider of allergy immunotherapy products and services, today announced that the US Food and Drug Administration (FDA) has approved Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) sublingual allergy immunotherapy tablet. Oralair is indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top